GLOW2 – Zenkuda improved the DRSS score irrespective of the use of GLP-1 medications, showing promising efficacy for real-world use 8 3.8% 2.8% 60.0% 64.3% 0% 25% 50% 75% GLP-1 use No GLP-1 use Sham Zenkuda Sham GLP-1 use (n=53); Sham No GLP-1 use (n=72). Zenkuda GLP-1 use (n=60); Zenkuda no GLP-1 use (n=70); Note: Percentages are 100*n/N. Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Proportion of patients with ≥2 -Step improvement in DRSS from Baseline to Week 48, by concomitant GLP-1 medication use GLOW2 Figure 6